Press Release | Frontier Medicines - Part 2

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

August 27, 2025/in 2024, Press Release/by eallison

April 9, 2024

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

August 27, 2025/in 2024, Press Release/by eallison

March 21, 2024

Frontier Medicines to Participate in Upcoming Investor Conferences

August 27, 2025/in 2024, Press Release/by eallison

February 27, 2024

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

August 27, 2025/in 2024, Press Release/by eallison

February 22, 2024

Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference

August 27, 2025/in 2024, Press Release/by eallison

January 3, 2024

Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer

August 27, 2025/in 2023, Press Release/by eallison

May 8, 2023

Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting

August 27, 2025/in 2023, Press Release/by eallison

April 16, 2023

Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting

August 27, 2025/in 2023, Press Release/by eallison

March 14, 2023

Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development

August 27, 2025/in 2023, Press Release/by eallison

February 28, 2023

Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie

August 27, 2025/in 2023, Press Release/by eallison

January 5, 2023